Portfolio Lab

GSK plc

  • Stock
  • Ticker GSK
  • ISIN US37733W2044
  • NYSE
  • US listing in dollars (ADR)

Health care · Pharmaceuticals · United Kingdom

$47.76 −0.13%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of GSK plc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

GSKGlobal equities (VT)

$10,000 grew to $15,790. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −50.1% in 09/2022, measured from the peak in 04/2022. It took 45 months to get back to the old peak.

1-year return
+7.3%
5-year return p.a.
+2.3%
10-year return p.a.
+4.7%
Volatility p.a.
21.8%
Largest decline
−50.1%

Financial statements

Amounts in £ millions from the company's annual financial reports, earnings per share in £ per ordinary share

Fiscal year202020212022202320242025
Income statement
Revenue34,09934,11429,32430,328––
Gross profit22,39522,51119,77021,76322,32823,650
Operating income7,7836,2016,4336,7454,0217,932
Net income6,3885,09615,6215,3082,9516,289
Earnings per share1.140.873.661.200.621.39
Balance sheet
Total assets80,43179,10360,14659,00559,46361,118
Liabilities59,62357,76150,05046,21046,37745,162
Equity20,80821,34210,09612,79513,08615,956
Cash6,2924,2743,7232,9363,8703,397
Long-term debt23,42520,57217,03515,20514,63714,708
Cash flow
Operating cash flow8,4417,9527,4036,7686,5547,741
Capital expenditure-1,226-1,172-1,143-1,314-1,399-1,348
Free cash flow7,2156,7806,2605,4545,1556,393

Annual returns

Best year 2025 at +51.2%, weakest 2022 at −33.4%. 5 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€86bn
Market cap in trading currency
$94.8bn
Enterprise value
$114bn
P/E
12.8
P/S
–
P/B
4.41
EV/Sales
–
EV/EBITDA
–
Earnings yield
7.8%
FCF yield
8.9%

Results (latest fiscal year)

Revenue
–
Gross profit
$31.0bn
EBITDA
–
Net income
$7.50bn
Earnings per share
$1.82
Revenue growth
–
Earnings growth
+122.0%

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
38.0%
Return on assets
9.4%

Balance sheet and cash flow

Cash
$4.46bn
Financial debt
$23.3bn
Debt/equity %
108
Current ratio
0.82
Book value per share
$5.31
Operating cash flow
$10.2bn
Free cash flow
$8.39bn

Dividend

Dividend yield
3.87%
Dividend (12 months)
$1.85
Yield (12 months)
3.87%
Payout ratio
45%
Ex-dividend date
13 Nov 2026

Shares and trading

Shares outstanding
4.05bn
Volume
2.74m
Avg. volume 3 months
4.04m
Relative volume
0.7

Price and technicals

Price
$47.76
1 day
−0.1%
52-week high
$61.18
52-week low
$46.11
Distance to 52-week high
−21.9%
Distance to 52-week low
+3.6%
Distance to 50-day line
−3.1%
Distance to 200-day line
−8.6%
RSI (14)
39
Volatility 1M
29.0%

Performance

1 week
−5.3%
1 month
−6.7%
3 months
−7.8%
6 months
−7.0%
YTD
−2.6%
1 year
+3.1%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has GSK performed since 11/2016?

$10,000 grew to $15,790 by 20 Nov 2026, which is +4.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is GSK?

Volatility was 21.8% per year, measured on monthly returns. The largest decline from a peak was −50.1%, with the low in 09/2022.

How does GSK compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, GSK returned +4.7% at 21.8%. The correlation of monthly returns was 0.37; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

GSK plc (GSK): Return and risk | Portfolio Lab